Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.
Prog Mol Biol Transl Sci. 2012;111:1-26. doi: 10.1016/B978-0-12-398459-3.00001-0.
The technology for generation of induced pluripotent stem cell (iPSC) from somatic cells emerged to circumvent the ethical and immunological limitations of embryonic stem cell (ESC). The recent progress of iPSC technology offers an unprecedented tool for regenerative medicine; however, integrating viral-driven iPSCs prohibits clinical applications by their genetic alterations and tumorigenicity. Various approaches including nonintegrating, nonviral, and nongenetic methods have been developed for generating clinically compatible iPSCs. In addition, approaches for using more clinically convenient or compatible source cells replacing fibroblasts have been actively pursued. While iPSC and ESC closely resemble in genomic, cell biologic, and phenotypic characteristics, these two pluripotent stem cells are not identical in terms of differentiation capacity and epigenetic features. In this chapter, we deal with the current techniques of generating iPSCs and their various characteristics.
体细胞诱导多能干细胞(iPSC)技术的出现,规避了胚胎干细胞(ESC)的伦理和免疫限制。iPSC 技术的最新进展为再生医学提供了前所未有的工具;然而,病毒驱动的 iPSC 因其遗传改变和致瘤性而禁止临床应用。已经开发了各种方法,包括非整合、非病毒和非遗传方法,用于生成临床上兼容的 iPSC。此外,还积极寻求使用更方便或更相容的临床来源细胞替代成纤维细胞的方法。虽然 iPSC 和 ESC 在基因组、细胞生物学和表型特征上非常相似,但这两种多能干细胞在分化能力和表观遗传特征方面并不完全相同。在本章中,我们将介绍生成 iPSC 的当前技术及其各种特性。